Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 94

Sort by

Sort Order Select

Journal Articles

Combination of Minimal Residual Disease By Flow Cytometry before and after Hematopoietic Stem Cell Transplantation Predicts Survival in Patients with Acute Myeloid Leukemia

Claudia Nuñez-Torron stock, Carlos Jiménez, Fernando Martín Moro, Juan Marquet, Miguel Piris-Villaespesa, Clara Lopez Hernandez, Alejandro Luna, Valentín García Gutiérrez, Sr., Anabelle Chinea, Maria Gemma Moreno Jimenez, Javier López, Pilar Herrera Puente

Blood (2024) 144 (Supplement 1): 7445.

https://doi.org/10.1182/blood-2024-210576

Published: 2024

Journal Articles

Observational, Retrospective and Multicenter Analysis of Spanish CML Group , in Patients with Chronic Myeloid Leukemia in Treatment-Free Remission after Discontinuation of Bosutinib

Gonzalo Maortua Langdon, Raquel De Paz, Pilar Giraldo, Blanca Xicoy, Joaquin Martinez Lopez, Guiomar Bautista Carrascosa, Jose Maria Alonso Alonso, Maria Soledad Noya Pereira, Magdalena Sierra Pacho, Raul Perez Lopez, Silvana Daniela Saavedra Gerosa, Valle Gomez G De Soria, Natalia De Las Heras, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 6604.

https://doi.org/10.1182/blood-2024-208460

Published: 2024

Journal Articles

Prevalence and Characteristics of Cutaneous Mastocytosis in Adult-Onset Mastocytosis in the Skin

Pablo Palomo Rumschisky, Lucia Bolea, Blanca De Felipe, Beatriz Astibia Mahillo, Fernando Martín Moro, Jesus Villarrubia Espinosa, Valentín García Gutiérrez, Sr., Ander Arteagoitia, Monica Garcia-Cosio, David González-De-Olano, Asunción Ballester, Bibiana Pérez García, Almudena Santón, Laura Carpio, Pilar Herrera Puente, Maria Gemma Moreno Jimenez, Javier López, Miguel Piris-Villaespesa

Blood (2024) 144 (Supplement 1): 6654.

https://doi.org/10.1182/blood-2024-202097

Published: 2024

Journal Articles

Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 3149.

https://doi.org/10.1182/blood-2024-205681

Published: 2024

Journal Articles

Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

Lucia Bolea, Alejandro Luna, Enrique Blanco, Valentín García Gutiérrez, Sr., Anabelle Chinea, Begoña Hijono, Maria Luisa Palacios-Berraquero, Pablo Palomo Rumschisky, Blanca De Felipe, Lucía Pérez-Lamas, Carlos Jiménez, Beatriz Astibia Mahillo, Alejandro Zurdo-Castronuño, Maria Piñero, Rut Corrales, Pilar Herrera, Javier López

Blood (2024) 144 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2024-206026

Published: 2024

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience

Elias Jabbour, Delphine Rea, Mouna Bardey-Kanaan, Romuald Soichez, Nhan Thanh Nguyen, Deborah Kelly, Federica Rizzo, Petros Patos, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 3816.

https://doi.org/10.1182/blood-2024-200256

Published: 2024

Journal Articles

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Thomas W. LeBlanc, Hannah Collacott, Valentín García Gutiérrez, Sr., Ned Weinshenker, Ruth Fein Revell, Alicia O'Neill, Anna P Cardellino, Shiyuan Zhang, Dwaipayan Patnaik, Melissa Ross

Blood (2024) 144 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2024-206086

Published: 2024

Journal Articles

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lucía Pérez-Lamas, Adrian Segura Diaz, Regina García Delgado, Alberto Alvarez-Larran, María Alicia Senin, Elvira Mora, Maria Laura Fox, Irene Pastor Galan, Gemma Azaceta, Sara Garrido Paniagua, Raul Perez Lopez, Diana Margarita Trejos Carvajal, Anna Angona, Carmen Albo Lopez, Pablo Lorente Alegre, Míriam Vara, Juan Antonio Juan Vera Goñi, Dunia De Miguel Llorente, Angeles Fernández Rodríguez, Alberto Marin Sanchez, Adriana Hernando Megido, Maria Teresa Gómez Casares, Ruth Stuckey, Gonzalo Carreño, Natalia De Las Heras Rodriguez, Blanca Xicoy, Manuel Perez Encinas, Raquel Mata Serna, Lucia Nuñez Martin-Buitrago, Francisca Ferrer Marin, Neus Amer Salas, Carolina Guillén Rienda, Patricia Velez, Laura Lamarca Eraso, Sandra Martín, Iryna Luts Khoroz, Erik De Cabo López, Angela Gil, Sofía Martín-Consuegra Ramos, Fernando Marco De Lucas, Maria José Otero Martinez-Fornes, María Luisa Martín Mateos, Teresa Arquero, Elena Cabezudo Pérez, Luis Antonio López Gómez, Angela Martinez Hellin, Aurelia Tejedor, Esther Herrera de Pablo, Maria Isabel Mata Vazquez, Inmaculada Castillo Valero, Maria Jose Fernández, Carlos Aguilar, Marta Santaliestra, Antonio Garcia Menchon, Begona Navas Elorza, Maria Antonia Duran, María Pérez Sala, Teresa Hernández Santamaría, Mª Ángeles Muñoz Jarreño, Julio Dávila-Valls, Williana Torres Jiménez, Joan Alfons Gonzálvez Fernández, Hugo Alexander Torres Mantilla, Teresa Cobo Rodríguez, Aitor Abuin Blanco, Francisco Pérez, María José Llácer Ferrandis, Paola Beneit Villena, Raisa Peralta, Federico Herrera, Eloi Cañamero Giro, Reyes Jimenez Barcenas, Mercedes Gasior Kabat, Sonia González De Villambrosia, Mariana Teresa Tercero-Mora Rodriguez, Marina Menéndez Cuevas, Beatriz Cuevas Ruiz, Marta Fonseca-Santos, Sonia Garcés Piquer, Rosalía Delapuerta, Alvaro Lorenzo Vizcaya, Juan Carlos Hernandez Boluda, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2024-200698

Published: 2024

Journal Articles

Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

Blood (2024) 144 (Supplement 1): 241.

https://doi.org/10.1182/blood-2024-198336

Published: 2024

Journal Articles

Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells

Beatriz Astibia Mahillo, María-Jesús Blanchard, Miguel Piris Villaespesa, Pablo Palomo Rumschisky, Jesús Villarrubia Espinosa, Valentín García Gutiérrez, Sr., Ana Jiménez, Mónica García-Cosío, Ernesto Roldán Santiago, Eulalia Rodríguez Martín, María Talavera Yagüez, Gemma Moreno Jiménez, Javier López, Fernando Martín Moro

Blood (2024) 144 (Supplement 1): 3349.

https://doi.org/10.1182/blood-2024-210589

Published: 2024

Journal Articles

Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

Blood (2024) 144 (Supplement 1): 4549.

https://doi.org/10.1182/blood-2024-205800

Published: 2024

Journal Articles

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Blood (2023) 142 (Supplement 1): 3163.

https://doi.org/10.1182/blood-2023-188875

Published: 2023

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study

Lucía Pérez-Lamas, Adrian Segura Diaz, Elvira Mora, Marta Hidalgo Soto, Antonio Paz Coll, Natalia De Las Heras, Montse Cortes, Patricia Velez Tenza, Magdalena Sierra Pacho, María Alicia Senin, Anna Angona, Carlos Cervero, Raquel De Paz Arias, Araceli Salamanca Cuenca, Marta Santaliestra, Javier López Marin, Luis Felipe Casado Montero, Valentín García Gutiérrez

Blood (2023) 142 (Supplement 1): 3177.

https://doi.org/10.1182/blood-2023-187412

Published: 2023

Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 623.

https://doi.org/10.1182/blood-2023-179160

Published: 2023

Journal Articles

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Lucía Pérez-Lamas, Juan Carlos Hernandez Boluda, Luis Felipe Casado Montero, Maria Teresa Gómez Casares, Rosa Ayala, Blanca Xicoy, Francisca Ferrer Marin, Guillermo Orti, Raquel De Paz Arias, Santiago Osorio Prendes, Raul Perez Lopez, Elvira Mora, Concepción Ruiz Nuño, Antonio Jimenez Velasco, Concepcion Boque, Magdalena Sierra Pacho, Joaquin Martinez Lopez, Valentin Garcia Gutierrez

Blood (2023) 142 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2023-184989

Published: 2023

Journal Articles

Correlation of TCR Repertoire Diversity with Myeloid Gene Mutations in Chronic and Advanced Phase Myeloproliferative Neoplasms

Miguel Piris-Villaespesa, Juan Marquet, Val Fernandez-Lanza, Valentín García Gutiérrez, Carlos Jimenez, Francisco J del Castillo, Gloria Muñoz, Javier López

Blood (2023) 142 (Supplement 1): 6345.

https://doi.org/10.1182/blood-2023-189836

Published: 2023

Journal Articles

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Michael Mauro, Jorge E. Cortes, Jane F. Apperley, Valentín García Gutiérrez, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus

Blood (2022) 140 (Supplement 1): 6757–6759.

https://doi.org/10.1182/blood-2022-169110

Published: 2022

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

NARROW

Combination of Minimal Residual Disease By Flow Cytometry before and after Hematopoietic Stem Cell Transplantation Predicts Survival in Patients with Acute Myeloid Leukemia

Observational, Retrospective and Multicenter Analysis of Spanish CML Group , in Patients with Chronic Myeloid Leukemia in Treatment-Free Remission after Discontinuation of Bosutinib

Prevalence and Characteristics of Cutaneous Mastocytosis in Adult-Onset Mastocytosis in the Skin

Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia

Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells

Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Correlation of TCR Repertoire Diversity with Myeloid Gene Mutations in Chronic and Advanced Phase Myeloproliferative Neoplasms

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only